Results 1 to 10 of about 694 (158)

A comparative study of efficacy and tolerability of cetirizine and bilastine in patients of allergic rhinitis: An open-label, randomized, parallel-group study [PDF]

Perspectives in Clinical Research
Purpose: Allergic rhinitis (AR) is a type 1 allergic disease of the nasal mucosa, characterized by paroxysmal repetitive sneezing, watery rhinorrhea, and nasal blockage with the prevalence of 25% worldwide.
Sneha P. Pawar, Punam A. Gosavi, Mrunalini Vinay Kalikar   +2 more
doaj   +2 more sources

Efficacy and Safety of Bilastine in the Treatment of Allergic Rhinitis: A Systematic Review and Meta-analysis

Frontiers in Pharmacology, 2022
Bilastine is a non-sedating second generation H1 oral antihistamine (OAH) for treating allergic rhinitis (AR) patients. The effect of bilastine has not previously been evaluated in a meta-analysis. The aim of this review was to determine the efficacy and
Baharudin Abdullah, Mohd Khairi Md Daud, Mohd Noor Norhayati   +2 more
exaly   +3 more sources

Comparative study of efficacy and safety of cetirizine and bilastine in patients of chronic spontaneous urticaria: Open-label, randomized, parallel-group study [PDF]

Perspectives in Clinical Research, 2023
Purpose: Bilastine is a novel second-generation antihistaminic. Very few studies in Indian population have compared the safety and efficacy of bilastine with other second-generation antihistaminic like cetirizine.
Vishakha V Sinha, Mrunalini Vinay Kalikar, Jayesh Ishwardas Mukhi, Akhil Bhagwan Giradkar, Smita Sontakke   +4 more
doaj   +2 more sources

Efficacy and safety of bilastine in Japanese patients with chronic spontaneous urticaria: A multicenter, randomized, double-blind, placebo-controlled, parallel-group phase II/III study

Allergology International, 2017
Background: Bilastine, a novel non-sedating second-generation H1-antihistamine, has been widely used in the treatment of allergic rhinoconjunctivitis and urticaria with a recommended dose of 20 mg once daily in most European countries since 2010.
Michihiro Hide, Masutaka Furue, Akiko Yagami   +2 more
exaly   +3 more sources

The new bilastine eye drop formulation protects against conjunctival dehydration and promotes corneal wound healing in a comparative in vitro study [PDF]

Scientific Reports
Bilastine is a non-sedating, highly selective H1-antihistamine with proven efficacy and safety in treating allergic rhinoconjunctivitis and urticaria in adults and children.
Eider Arana, Ana Gonzalo, Noelia Andollo, Miguel Pérez-Garrastachu, Francisco Otero-Espinar, Victoria Díaz-Tomé, Felipe Goñi-de-Cerio, Paloma Gómez-Fernández, Gonzalo Hernández, Tatiana Suárez-Cortés   +9 more
doaj   +2 more sources

Effectiveness, safety, and cost-effectiveness of fixed-dose combination of montelukast–bilastine versus montelukast–levocetirizine in allergic rhinitis: A prospective, randomized, open-label, parallel-group study [PDF]

Perspectives in Clinical Research
Introduction: Several fixed-dose combinations (FDCs) have been available for the treatment of allergic rhinitis (AR), of which montelukast and levocetirizine is one of the highly prescribed FDC.
Ganesh Natthuji Dakhale, Chaitali A. Chindhalore, Mohit Kumar, Vijay Bidkar   +3 more
doaj   +2 more sources

Effectiveness, Safety, and Tolerability of Bilastine Up-Dosing in Chronic Spontaneous Urticaria Uncontrolled with Licensed Doses of Other Second-Generation Antihistamines—An Institution-Based, Open-Label, Single-Group Longitudinal Trial [PDF]

Indian Dermatology Online Journal
Background: Bilastine 20 mg daily is a second-generation antihistamine (sgAH) approved for chronic spontaneous urticaria (CSU). Up-dosing to 40 or 80 mg daily is recommended in uncontrolled patients.
Sankha S. Chakraborty, Indrashis Podder, Manisha Das, Arunima Dhabal   +3 more
doaj   +2 more sources

Efficacy and safety of switching to bilastine, an H1-antihistamine, in patients with refractory chronic spontaneous urticaria (H1-SWITCH): a multicenter, open-label, randomized, parallel-group comparative study [PDF]

Frontiers in Immunology
BackgroundFor treating patients with refractory chronic spontaneous urticaria (CSU) resistant to standard doses of 2nd generation H1-antihistamines (H1AH) the International and Japanese guidelines recommend increasing H1AH dose.
Atsushi Fukunaga, Atsushi Fukunaga, Yasumasa Kakei, Yasumasa Kakei, Sae Murakami, Yuji Kan, Koji Masuda, Masatoshi Jinnin, Ken Washio, Hiroo Amano, Tohru Nagano, Akihisa Yamamoto, Toshihiro Otsuka, Shunsuke Takahagi, Motoi Takenaka, Naoko Ishiguro, Koremasa Hayama, Naoko Inomata, Yukinobu Nakagawa, Akiko Sugiyama, Michihiro Hide, Michihiro Hide   +21 more
doaj   +2 more sources

Efficacy and safety of bilastine in Japanese patients with perennial allergic rhinitis: A multicenter, randomized, double-blind, placebo-controlled, parallel-group phase III study

Allergology International, 2017
Background: Bilastine, a novel non-sedating second-generation H1 antihistamine, has been approved in most European countries since 2010. This study aimed to evaluate the superiority of bilastine over placebo in Japanese patients with perennial allergic ...
Minoru Gotoh, Kimihiro Okubo, Yasuyuki Nomura   +2 more
exaly   +3 more sources

A Prospective Randomized Non-Blinded Study of Safety and Efficacy of Bilastine Up-Dosing (40 mg) Versus Combination of Bilastine 20 mg With Levocetirizine 5 mg in the Treatment of Chronic Spontaneous Urticaria

Indian Journal of Dermatology
Introduction: Chronic spontaneous urticaria (CSU) is the most commonly diagnosed skin condition in dermatology outpatient departments. Second-generation antihistamines are shown to be effective in the control of CSU.
Boggarapu Sneha, Murali Narasimhan, Priya Cinna T. Durai, Ramachandran Ramakrishnan   +3 more
doaj   +2 more sources